🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

133 results for “Boehringer” Clear

  1. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim International GmbH

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  2. A study to test whether multiple doses of BI 456906 have an effect on cardiac safety in people with overweight or obesity.

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  3. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim International GmbH

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  4. An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Empagliflozin Tablets 25 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Jardiance (Empagliflozin) 25 mg film-coated tablets, Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein Germany, in healthy adult, human subjects under fasting condition.

    Pharma Mar S.A.

    Diabetes

    phase 1 other active

    1 trial

  5. BI 1015550, NERANDOMILAST

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 small molecule active

    1 trial

  6. Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)

    Boehringer Ingelheim International GmbH

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  7. DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy

    Boehringer Ingelheim International GmbH

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  8. DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

    Boehringer Ingelheim International GmbH

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  9. DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

    Boehringer Ingelheim International GmbH

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  10. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim International GmbH

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  11. Randomized, open-label, single-dose, two-period, cross-over, bioequivalence study comparing Linagliptin 5 mg film-coated tablets (Vipharm S.A.) to Trajenta® 5 mg film-coated tablets (Boehringer Ingelheim) in healthy volunteers under fasting conditions.

    Pharm Research Associates (UK) Limited

    Bioequivalence study in healthy volunteers under fasting conditions

    phase 1 other active

    1 trial

  12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim International GmbH

    Plaque psoriasis

    phase 1 other active

    1 trial

  13. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim International GmbH

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources